BIO
Bio-Rad Laboratories, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q4 2015 | 43Q | $136 | $306 | +125% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $320 | $306 | -4% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $320 | $306 | -4% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $320 | $306 | -4% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $320 | $306 | -4% |
| Citadel Advisors | Q4 2024(8Q snapshot) | 6Q | $350 | $306 | -13% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 2× in & out | Q4 2025 | Q1 2026 | → $265 | -15% |
| Maverick Capital 3× in & out | Q1 2023 | Q3 2023 | → $395 | -15% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at BIO-RAD LABORATORIES, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 13, 2026 — the most recent Form 4 on file — not from today.
- Form 40002024911-26-000002May 13, 2026
- Form 40001396867-26-000002Apr 28, 2026
- Form 40002019843-26-000002Apr 28, 2026
- Form 40001239182-26-000003Apr 23, 2026
- Form 40001703469-26-000002Apr 23, 2026
- Form 40001190642-26-000002Apr 23, 2026
- Form 40001343989-26-000002Apr 23, 2026
- Form 40002022345-25-000008Nov 10, 2025
- Form 40001453524-25-000007Oct 28, 2025
- Form 40001993147-25-000006Oct 21, 2025
- Form 40001993147-25-000004Sep 9, 2025
- Form 40001396867-25-000004Sep 9, 2025
- Form 40001976271-25-000006Sep 9, 2025
- Form 40002022345-25-000006Sep 9, 2025
- Form 40001924980-25-000006Sep 9, 2025
Fundamentals
XBRL · Bio-Rad Laboratories, Inc.Annual figures sourced directly from Bio-Rad Laboratories, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for BIO-RAD LABORATORIES, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportApr 30, 2026
- 8-KMaterial eventApr 30, 2026
- 8-KMaterial eventApr 24, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTMar 25, 2026
- 8-KMaterial eventFeb 19, 2026
- 10-KAnnual reportFeb 13, 2026
- 8-KMaterial eventFeb 12, 2026
- 10-QQuarterly reportOct 29, 2025
- 8-KMaterial eventOct 29, 2025
- 8-KMaterial eventSep 30, 2025
- 8-KMaterial eventAug 26, 2025
- 10-QQuarterly reportJul 31, 2025
- 8-KMaterial eventJul 31, 2025
- 8-KMaterial eventJul 28, 2025
- 8-KMaterial eventJun 30, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Bridgewater Associates | Q2 2026 | open | $248 | $306 | +24% |
| Two Sigma Investments | Q2 2026 | open | $248 | $282 | +14% |
| Point72 Asset Management | Q4 2025 | Q1 2026 | $313 | $265 | -15% |
| Bridgewater Associates | Q4 2025 | Q1 2026 | $317 | $257 | -19% |
| Citadel Advisors | Q4 2024 | open | $350 | $282 | -20% |
| Point72 Asset Management | Q4 2024 | Q3 2025 | $350 | $287 | -18% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | $320 | $243 | -24% |
| D.E. Shaw | Q3 2024 | open | $320 | $282 | -12% |
| AQR Capital Management | Q3 2024 | open | $320 | $282 | -12% |
| Millennium Management | Q3 2024 | open | $320 | $282 | -12% |
| Maverick Capital | Q1 2023 | Q3 2023 | $463 | $395 | -15% |
| Bridgewater Associates | Q2 2022 | Q2 2024 | $502 | $294 | -41% |
| Maverick Capital | Q1 2021 | Q4 2021 | $650 | $754 | +16% |
| Maverick Capital | Q3 2020 | Q4 2020 | $506 | $597 | +18% |
| Bridgewater Associates | Q1 2018 | Q2 2019 | $237 | $292 | +23% |
| Bridgewater Associates | Q4 2015 | Q1 2016 | $136 | $125 | -8% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.